Loading company…
Targanta Therapeutics developed antibacterial treatments, including the antibiotic Oritavancin.
Founded in 1997 in Cambridge, US, Targanta Therapeutics focused on antibacterial treatments, particularly Oritavancin for resistant Gram-positive bacteria. The company raised USD 57.5 mn in its October 2007 IPO. The Medicines Co. acquired it in February 2009.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in